{"doi":"10.3390/cells10071648","title":"ROCK Inhibition as Potential Target for Treatment of Pulmonary Hypertension","abstract":"<jats:p>Pulmonary hypertension (PH) is a cardiovascular disease caused by extensive vascular remodeling in the lungs, which ultimately leads to death in consequence of right ventricle (RV) failure. While current drugs for PH therapy address the sustained vasoconstriction, no agent effectively targets vascular cell proliferation and tissue inflammation. Rho-associated protein kinases (ROCKs) emerged in the last few decades as promising targets for PH therapy, since ROCK inhibitors demonstrated significant anti-remodeling and anti-inflammatory effects. In this review, current aspects of ROCK inhibition therapy are discussed in relation to the treatment of PH and RV dysfunction, from cell biology to preclinical and clinical studies.</jats:p>","journal":"Cells","year":2021,"id":602572,"datarank":0.5333022092234121,"base_score":3.5553480614894135,"endowment":3.5553480614894135,"self_citation_contribution":0.5333022092234121,"citation_network_contribution":0.0,"self_endowment_contribution":0.5333022092234121,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":34,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1545394,"name":"Jaqueline S. da Silva","orcid":"0000-0003-3946-4753","position":1,"is_corresponding":false},{"id":1545396,"name":"Susumu Z. Sudo","orcid":null,"position":2,"is_corresponding":false},{"id":1545397,"name":"Aimeé D. Santos","orcid":"0000-0002-1008-2420","position":3,"is_corresponding":false},{"id":1545398,"name":"Gabriel F. Gomide","orcid":"0000-0002-9428-5443","position":4,"is_corresponding":false},{"id":1545399,"name":"Mauro P. L. de Sá","orcid":null,"position":5,"is_corresponding":false},{"id":1545400,"name":"Gisele Zapata-Sudo","orcid":"0000-0002-9066-5027","position":6,"is_corresponding":false},{"id":1545392,"name":"Tadeu L. Montagnoli","orcid":"0000-0003-1196-0149","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"ROCK Inhibition as Potential Target for Treatment of Pulmonary Hypertension","abstract":"<jats:p>Pulmonary hypertension (PH) is a cardiovascular disease caused by extensive vascular remodeling in the lungs, which ultimately leads to death in consequence of right ventricle (RV) failure. While current drugs for PH therapy address the sustained vasoconstriction, no agent effectively targets vascular cell proliferation and tissue inflammation. Rho-associated protein kinases (ROCKs) emerged in the last few decades as promising targets for PH therapy, since ROCK inhibitors demonstrated significant anti-remodeling and anti-inflammatory effects. In this review, current aspects of ROCK inhibition therapy are discussed in relation to the treatment of PH and RV dysfunction, from cell biology to preclinical and clinical studies.</jats:p>","is_dataset_classified":null,"base_score":3.5553480614894135,"endowment":3.5553480614894135,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"34209333","pmcid":"PMC8303917","openalex_id":"https://openalex.org/W3175349267","authors":[],"funders":[{"funder_name":"Conselho Nacional de Desenvolvimento Científico e Tecnológico","grant_id":"428102/2018-2","title":null},{"funder_name":"Fundacão Carlos Chagas Filho de Amparo à Pesquisa do estado do Rio de Janeiro","grant_id":"E-26/202.906/2017","title":null}],"total_grants":2,"fwci":3.1284,"citation_percentile":0.92954828,"influential_citations":0,"citation_trend":[{"year":2021,"count":3},{"year":2022,"count":10},{"year":2023,"count":8},{"year":2024,"count":3},{"year":2025,"count":8},{"year":2026,"count":2}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/2073-4409/10/7/1648/pdf?version=1625061816","host_type":"journal"},{"url":"https://www.mdpi.com/2073-4409/10/7/1648/pdf?version=1625061816","host_type":"publisher"},{"url":"https://www.mdpi.com/2073-4409/10/7/1648/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/cells10071648","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/34209333","host_type":"repository"},{"url":"https://doaj.org/article/5d764c82c4714c76b66ab2b7c006dfc8","host_type":"repository"},{"url":"https://dx.doi.org/10.3390/cells10071648","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8303917","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC8303917","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC8303917?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Pulmonary Hypertension Research and Treatments","Protein Kinase Regulation and GTPase Signaling","PI3K/AKT/mTOR signaling in cancer","Animals","Clinical Trials as Topic","Disease Models, Animal","Drug Approval","Humans","Hypertension, Pulmonary","Protein Kinase Inhibitors","rho-Associated Kinases"],"mesh_terms":["Animals","Clinical Trials as Topic","Disease Models, Animal","Humans","Hypertension, Pulmonary","Drug Approval","Protein Kinase Inhibitors","rho-Associated Kinases"],"keywords":["Pulmonary hypertension","Medicine","Vasoconstriction","Inflammation","Ventricle","Hypoxic pulmonary vasoconstriction","Pulmonary vasculature","Ventricular remodeling","Disease","Heart failure","Cardiology","Pharmacology","Internal medicine","Rock","Right Ventricle Dysfunction"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-29T19:44:18.006469Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}